Clinical and biological effects of treatment with amifostine in myelodysplastic syndromes

Rosangela Invernizzi, Alessandro Pecci, Erica Travaglino, Paolo G. Gobbi, Lucia Malabarba, Isabella Ramajoli, Edoardo Ascari

Research output: Contribution to journalArticlepeer-review


We treated six patients with primary myelodysplastic syndrome (MDS) with amifostine (200 mg/m2 i.v./three times a week for three consecutive weeks). Neutrophil counts were more frequently increased than platelet and reticulocyte counts, but no reduction of the transfusion requirement was observed. Significant reduction of the marrow blasts was observed in one case of refractory anaemia with excess of blasts. In vitro stimulation of haematopoiesis was observed in five cases. The apoptotic rate of marrow cells was significantly diminished even after the first course. Our findings show fairly good clinical and biological response to amifostine in MDS.

Original languageEnglish
Pages (from-to)246-250
Number of pages5
JournalBritish Journal of Haematology
Issue number1
Publication statusPublished - 2002


  • Amifostine
  • Apoptosis
  • Haematopoietic progenitors
  • Myelodysplastic syndrome
  • Therapy

ASJC Scopus subject areas

  • Hematology


Dive into the research topics of 'Clinical and biological effects of treatment with amifostine in myelodysplastic syndromes'. Together they form a unique fingerprint.

Cite this